非布索坦的治疗效果

Gout is a common and complex type of arthritis. People of all ages may suffer from gout. Gout patients often experience sudden joint pain at night. The pain is quite high and feels like a big toe being burned. If not treated in time, the consequences of delay will be that the pain will become stronger and more unbearable. And it can also endanger other normal functions of the body. Also called febuxostat, it is an anti-gout drug. Because febuxostat has a significant inhibitory effect on both oxidized and reduced XOR, its uric acid-lowering effect is more powerful and long-lasting. Therefore, febuxostat can be used to treat chronic hyperuricemia in gout. On September 4, 2018, the domestic CFDA officially approved the listing of febuxostat. The domestic febuxostat tablets are also called fibril.

Febuxostat is a new non-purine xanthine oxidase (XO) selective inhibitor that works by reducing blood urate concentration. It is completely absorbed after oral administration and has a high utilization rate. Food and antacids have no significant effect on its absorption. Unlike allopurinol, its structure is a non-purine analogue, so it is selective in inhibiting xanthine oxidase and has little effect on other enzymes in purine or pyrimidine metabolism. This means that febuxostat is less likely to be affected by other factors and has a stable effect.

A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of febuxostat in gout. A total of 136 male and 17 female gout patients were randomly assigned to receive placebo or febuxostat (40, 80 or 120 mg/d). After 4 weeks, the test found that the serum uric acid concentration of patients in each dose group of febuxostat was significantly lower than before treatment, with the average decrease in each group from low to high dose. It was 37%, 44% and 59% lower, while patients in the placebo group only decreased by 2%; the vast majority of patients persisted in completing the trial, and the incidence of adverse reactions was similar to that in the placebo group, and most of these adverse reactions were mild and self-limiting, with common ones including diarrhea, pain, back pain, headache and joint pain.